Sensorion SA closed a €60 million financing round, including a €20 million strategic investment from Sanofi, to advance a clinical program for SENS‑601 and other hearing‑loss candidates. The funding will support late‑stage development and expand Sensorion’s pipeline aimed at restoring and preventing sensorineural hearing loss. Sanofi’s investment signals major‑pharma interest in otology assets and provides Sensorion with both capital and a potential development partner. The cash infusion targets clinical readiness and could de‑risk Sensorion’s work as it seeks to validate disease‑modifying approaches for hearing disorders that currently lack approved regenerative therapies.